I think the point is that on the private expenditures, they cover some of the drugs that are not in the Quebec formulary, so it's hard to know exactly how you can divide those. There will certainly be savings on the part of the private sector, but we haven't really figured out exactly how that will be divided because of the differences in the coverage.
On October 17th, 2017. See this statement in context.